Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 03/06/2024 BST			5-day change	1st Jan Change
16.05 ^USD	+1.90%		+5.80%	+55.52%

05-28	Nurix Therapeutics, Inc. Appoints Paula G. O?Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer	CI
05-20	Nurix Therapeutics Names New Board Chair	MT

Nurix Therapeutics, Inc. Announces Resignation of Leon Chen as A Member of the Nominating and Corporate Governance Committee

June 01, 2021 at 09:12 pm

Nurix Therapeutics, Inc. announced On May 28, 2021, Leon Chen, Ph.D., advised the board of directors he would resign as a Class II director of the Board and as a member of the Nominating and Corporate Governance Committee of the Board effective immediately. The Resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

Latest news about Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. Appoints Paula G. O?Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer	05-28	CI
Nurix Therapeutics Names New Board Chair	05-20	MT
Nurix Therapeutics Announces Board Chair Transition	05-20	CI
Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target	05-14	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	04-12	MT
Sector Update: Health Care	04-12	MT
North American Morning Briefing : Big Banks Kick off Earnings Season	04-12	DJ
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	04-12	MT
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours	04-11	MT
Baird Adjusts Price Target on Nurix Therapeutics to $25 From $24, Maintains Outperform Rating	04-11	MT
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier	04-11	MT
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	04-10	CI
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M	04-10	MT
North American Morning Briefing : Traders Await -2-	04-10	DJ
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	04-09	DJ
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	04-09	CI
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	04-09	MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	04-09	CI
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years	04-02	MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration	04-02	DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences	04-02	CI
Nurix Therapeutics, Inc. Presents the Discovery and Chemical Structure of First-In-Class CBL-B Inhibitor NX-1607 at the American Chemical Society Meeting	03-20	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to S&P Biotechnology Select Industry Index	03-17	CI
Nurix Therapeutics Says US FDA Lifts Partial Clinical Hold on Phase 1 Trial of NX-2127	03-11	MT
Nurix Therapeutics : FDA Lifts Partial Clinical Hold on NX-2127 Study	03-11	DJ

Chart Nurix Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Nurix Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.05 USD

Average target price

24.67 USD

Spread / Average Target

+53.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NURIX THERAPEUTICS, INC.	+55.52%	934M
VERTEX PHARMACEUTICALS INCORPORATED	+15.55%	118B
REGENERON PHARMACEUTICALS, INC.	+12.66%	106B
BIONTECH SE	-2.53%	24.28B
ARGENX SE	+1.14%	21.96B
GENMAB A/S	-9.35%	18.16B
WUXI APPTEC CO., LTD.	-42.28%	16.37B
BEIGENE, LTD.	-18.92%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+6.19%	13.63B
SAREPTA THERAPEUTICS, INC.	+28.83%	12.27B

Bio Therapeutic Drugs